All In Biotech

Drug Trial Radar · NCT07431086

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, Tolerability, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity in the US

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Actual

Start

Mar 16, 2026

Primary completion

Nov 13, 2026

Study completion Dec 18, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Feb 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity. The study will test how safe and effective the study drug works compared to placebo in people who are overweight or obese but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much the study drug is in the blood at different times * How well the study drug works * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

Conditions

  • Overweight or Obesity

Interventions

  • OlatorepatideDrug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 30 weeks
  2. Severity of TEAEsTime frame: Up to approximately 30 weeks
  3. Maximum plasma Concentration (Cmax)Time frame: At week 15 and week 24
  4. Area Under the Concentration time curve from time 0 to 168 hours (AUC0-168h)Time frame: At week 15 and week 24

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Diablo Clinical Research - Flourish Research

    Walnut Creek, California

  • Clinical Site Partners, LLC DBA Flourish Research

    Winter Park, Florida

  • Flourish Research - San Antonio Medical Trials

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.